Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions - Schedule of Effective Date and Equity Fee Payble (Detail)

v3.7.0.1
Related Party Transactions - Schedule of Effective Date and Equity Fee Payble (Detail)
 3 Months Ended
Mar. 31, 2017
Helocyte Inc [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Mar. 20, 2015 [1]
Avenue Therapeutics, Inc. [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Feb. 17, 2015 [1]
Mustang Bio, Inc [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Mar. 13, 2015 [1]
Checkpoint Therapeutics, Inc [Member]  
Dividends, Paid-in-kind,Percentage 0.00% [2]
Dividends Payable, Date Declared Mar. 17, 2015 [1]
Cellvation Inc [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Oct. 31, 2016 [1]
Caelum Biosciences, Inc. [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Jan. 01, 2017 [1]
Cyprium Biosciences, Inc [Member]  
Dividends, Paid-in-kind,Percentage 2.50%
Dividends Payable, Date Declared Mar. 13, 2017 [1]
[1] Represents the effective date of each subsidiary’s Founders Agreement. While certain Founders Agreements may have been amended and restated subsequently, as described in the Company’s Form 10-K for the year ended December 31, 2016 filed with the SEC on March 16, 2017, each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement.
[2] Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.